公开(公告)号：WO2011033472A1

公开(公告)日：2011-03-24

申请号：PCT/IB2010054196

申请日：2010-09-16

Applicant: RANBAXY LAB LTD ,  SANWAL SUDHIR SINGH ,  KUMAR SARIDI MADHAVA DILEEP ,  SATHYANARAYANA SWARGAM ,  THAPER RAJESH KUMAR ,  PRASAD MOHAN

Inventor： SANWAL SUDHIR SINGH ,  KUMAR SARIDI MADHAVA DILEEP ,  SATHYANARAYANA SWARGAM ,  THAPER RAJESH KUMAR ,  PRASAD MOHAN

IPC: C07D403/06

CPC classification number: C07D403/06

Abstract: The present invention relates to salts of sunitinib and their preparation.

Abstract translation: 本发明涉及舒尼替尼的盐及其制备方法。

公开(公告)号：WO2011058525A3

公开(公告)日：2011-11-24

申请号：PCT/IB2010055155

申请日：2010-11-12

Applicant: RANBAXY LAB LTD ,  MURUGESAN BALAGURU ,  VEMPALI ANANDAM ,  SATHYANARAYANA SWARGAM ,  THAPER RAJESH KUMAR ,  PRASAD MOHAN

Inventor： MURUGESAN BALAGURU ,  VEMPALI ANANDAM ,  SATHYANARAYANA SWARGAM ,  THAPER RAJESH KUMAR ,  PRASAD MOHAN

IPC: C07D239/94

CPC classification number: C07D239/94

Abstract: The present invention relates to processes for the preparation of erlotinib hydrochloride Form A and erlotinib hydrochloride Form B.(I).

Abstract translation: 本发明涉及制备盐酸埃罗替尼形式A和盐酸埃洛替尼B型（I）的方法。

公开(公告)号：WO2006035277A2

公开(公告)日：2006-04-06

申请号：PCT/IB2005002784

申请日：2005-09-20

Applicant: RANBAXY LAB LTD ,  RAFEEQ MOHAMMAD ,  DE SHANTANU ,  SATHYANARAYANA SWARGAM ,  KUMAR YATENDRA

Inventor： RAFEEQ MOHAMMAD ,  DE SHANTANU ,  SATHYANARAYANA SWARGAM ,  KUMAR YATENDRA

IPC: C07D239/42 ,  A61K31/505 ,  A61P3/06

CPC classification number: C07D239/42

Abstract: Provided are processes for preparing amorphous rosuvastatin calcium from crystalline rosuvastatin calcium by simple crystallization processes. Also provided is a novel polymorphic form of rosuvastatin sodium, processes for preparing thereof and pharmaceutical compositions thereof.

Abstract translation: 提供了通过简单的结晶方法由结晶的瑞舒伐他汀钙制备无定形瑞舒伐他汀钙的方法。 还提供了瑞舒伐他汀钠的新型多晶型物，其制备方法及其药物组合物。

公开(公告)号：WO2014049586A2

公开(公告)日：2014-04-03

申请号：PCT/IB2013059017

申请日：2013-09-30

Applicant: RANBAXY LAB LTD

Inventor： VEMPALI ANANDAM ,  SANWAL SUDHIR SINGH ,  MURUGESAN BALAGURU ,  SATHYANARAYANA SWARGAM ,  THAPER RAJESH KUMAR ,  PRASAD MOHAN

IPC: C07D401/12

CPC classification number: C07D401/12 ,  C07C303/32

Abstract: The present invention provides hydrobromide salt of dabigatran etexilate and its process for the preparation. The present invention further provides crystalline Form I and crystalline Form II of hydrobromide salt of dabigatran etexilate and processes for their preparation. The present invention further relates to a process for the preparation of pharmaceutically acceptable salts, including methanesulfonate salt, of dabigatran etexilate using hydrobromide salt of dabigatran etexilate of the present invention.

Abstract translation: 本发明提供达比加群酯的氢溴酸盐及其制备方法。 本发明还提供了达比加群酯的氢溴酸盐的晶型I和结晶形式II及其制备方法。 本发明还涉及使用本发明的达比加群酯的氢溴酸盐制备达比加群酯的药学上可接受的盐，包括甲磺酸盐的方法。

公开(公告)号：WO2011092663A3

公开(公告)日：2011-12-29

申请号：PCT/IB2011050396

申请日：2011-01-28

Applicant: RANBAXY LAB LTD ,  JARYAL JAGDEV SINGH ,  SATHYANARAYANA SWARGAM ,  THAPER RAJESH KUMAR ,  PRASAD MOHAN ,  ZADE SACHIN DEORAO ,  SINGH AJAY SHANKAR

Inventor： JARYAL JAGDEV SINGH ,  SATHYANARAYANA SWARGAM ,  THAPER RAJESH KUMAR ,  PRASAD MOHAN ,  ZADE SACHIN DEORAO ,  SINGH AJAY SHANKAR

IPC: C07D213/81 ,  A61K31/4412

CPC classification number: C07D213/81 ,  G01N30/02

Abstract: The present invention provides dimethyl sulphoxide solvate of 4-(4-{3-[4-chloro- 3-(trifluoromethyl)phenyl]ureido }phenoxy)-N2 -methylpyridine-2-carboxamide, process for its preparation, pharmaceutical composition comprising it and its use for the treatment of cancer. The present invention also provides a novel HPLC method for the identification, quantification and isolation of related substances of sorafenib.

Abstract translation: 本发明提供4-（4- {3- [4-氯-3-（三氟甲基）苯基]脲基}苯氧基）-N2-甲基吡啶-2-甲酰胺的二甲基亚砜溶剂合物，其制备方法，包含它的药物组合物 并用于治疗癌症。 本发明还提供了用于鉴定，定量和分离索拉非尼相关物质的新型HPLC方法。

公开(公告)号：WO2006035286A3

公开(公告)日：2006-07-06

申请号：PCT/IB2005002843

申请日：2005-09-26

Applicant: RANBAXY LAB LTD ,  DE SHANTANU ,  TRIPATHI VINAYAK ,  SATHYANARAYANA SWARGAM ,  KUMAR YATENDRA

Inventor： DE SHANTANU ,  TRIPATHI VINAYAK ,  SATHYANARAYANA SWARGAM ,  KUMAR YATENDRA

IPC: A61K31/404 ,  A61K31/405 ,  A61P3/04 ,  A61P9/10 ,  C07D209/24

CPC classification number: C07D209/24

Abstract: The present invention provides processes for preparing enantiomerically pure fluvastatin sodium. The present invention also provides pharmaceutical compositions comprising the enantiomerically pure fluvastatin sodium for antagonizing HMG-CoA. In addition the present invention provides a novel polymorphic form of enantiomerically pure fluvastatin sodium.

Abstract translation: 本发明提供了制备对映体纯的氟伐他汀钠的方法。 本发明还提供了包含对映体纯的氟伐他汀钠用于拮抗HMG-CoA的药物组合物。 此外，本发明提供了对映体纯的氟伐他汀钠的新多晶型形式。

公开(公告)号：WO2014049585A2

公开(公告)日：2014-04-03

申请号：PCT/IB2013059016

申请日：2013-09-30

Applicant: RANBAXY LAB LTD

Inventor： VEMPALI ANANDAM ,  SANWAL SUDHIR SINGH ,  MURUGESAN BALAGURU ,  SATHYANARAYANA SWARGAM ,  THAPER RAJESH KUMAR ,  PRASAD MOHAN

IPC: C07D401/12

CPC classification number: C07D401/12 ,  C07C53/10 ,  C07C53/48 ,  C07C309/19 ,  C07D213/75

Abstract: The present invention relates to a process for the preparation of dabigatran etexilate. The present invention also relates to trifluoroacetate salt of dabigatran etexilate and a process for its preparation. The present invention further relates to crystalline Form I and crystalline Form II of trifluoroacetate salt of dabigatran etexilate and processes for their preparation. The present invention further relates to a process for the preparation of pharmaceutically acceptable salts, including methanesulfonate salt, of dabigatran etexilate.

Abstract translation: 本发明涉及制备达比加群酯的方法。 本发明还涉及达比加群酯的三氟乙酸盐及其制备方法。 本发明还涉及达比加群酯的三氟乙酸盐的晶型I和结晶形式II及其制备方法。 本发明还涉及制备达比加群酯的药学上可接受的盐，包括甲磺酸盐的方法。

公开(公告)号：WO2011058521A3

公开(公告)日：2011-07-07

申请号：PCT/IB2010055150

申请日：2010-11-12

Applicant: RANBAXY LAB LTD ,  SANWAL SUDHIR SINGH ,  KUMAR SARIDI MADHAVA DILEEP ,  SATHYANARAYANA SWARGAM ,  THAPER RAJESH KUMAR ,  PRASAD MOHAN

Inventor： SANWAL SUDHIR SINGH ,  KUMAR SARIDI MADHAVA DILEEP ,  SATHYANARAYANA SWARGAM ,  THAPER RAJESH KUMAR ,  PRASAD MOHAN

IPC: C07D403/06

CPC classification number: C07D403/06

Abstract: The present invention relates to a process for the preparation of crystalline Form I of the L-malic acid salt of sunitinib.

Abstract translation: 本发明涉及一种制备舒尼替尼的L-苹果酸盐的晶型I的方法。

公开(公告)号：WO2008068727A3

公开(公告)日：2008-12-31

申请号：PCT/IB2007054958

申请日：2007-12-06

Applicant: RANBAXY LAB LTD ,  HANDA AJAY KUMAR ,  SATHYANARAYANA SWARGAM ,  SINGLA AJAY KUMAR

Inventor： HANDA AJAY KUMAR ,  SATHYANARAYANA SWARGAM ,  SINGLA AJAY KUMAR

IPC: A61K9/20 ,  A61K9/10 ,  A61K9/48 ,  A61K31/4184

CPC classification number: A61K31/4184 ,  A61K9/2009 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2059

Abstract: The present invention relates to a pharmaceutical composition comprising candesartan cilexetil.

Abstract translation: 本发明涉及一种包含坎地沙坦碳酸酯的药物组合物。

公开(公告)号：WO2006030304A3

公开(公告)日：2006-12-07

申请号：PCT/IB2005002754

申请日：2005-09-16

Applicant: RANBAXY LAB LTD ,  DE SHANTANU ,  TRIPATHI VINAYAK ,  SATHYANARAYANA SWARGAM ,  JINDAL SHANTANU ,  KUMAR YATENDRA

Inventor： DE SHANTANU ,  TRIPATHI VINAYAK ,  SATHYANARAYANA SWARGAM ,  JINDAL SHANTANU ,  KUMAR YATENDRA

IPC: C07D209/24 ,  A61K31/404

CPC classification number: C07D209/24

Abstract: Provided are substantially amorphous fluvastatin sodium and amorphous Form R6 and R-14 of fluvastatin sodium. Also provided are crystalline forms of fluvastatin sodium designated as Forms R-1, R-2, R-3, R-4, R-5, R-7, R-8, R-9, R-10, R-11, R-12, R-13, R-15 and R-16 and an anhydrous crystalline form. Also provided are processes for preparing such polymorphic forms and pharmaceutical compositions thereof. Also provided are methods for antagonizing HMG-CoA comprising administering to a mammal therapeutically effective amounts of the compounds described herein.

Abstract translation: 提供的是基本上无定形的氟伐他汀钠和氟伐他汀钠的无定形R6和R-14。 还提供了称为晶型R-1，R-2，R-3，R-4，R-5，R-7，R-8，R-9，R-10，R-11的氟伐他汀钠的结晶形式 ，R-12，R-13，R-15和R-16以及无水结晶形式。 还提供了制备这种多晶型物及其药物组合物的方法。 还提供了用于拮抗HMG-CoA的方法，其包括向哺乳动物施用治疗有效量的本文所述的化合物。